JPRN-jRCTs031220436已完成Unknown
A comparative pharmacokinetic study of ciprofloxacin when taken with water and thickened water in healthy adult males.
Hida Noriko0 个研究点目标入组 6 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
Ciprofloxacin tablets may affect pharmacokinetics when taken in tablet form with thickened water.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 45age old(—)
- 性别
- Male
入选标准
- •1) Age: The applicant must be at least 20 years old and less than 45 years old at the time of obtaining consent.
- •2) Gender: Male
- •3) Who have the capacity to give consent, abide by the rules of compliance during participation in the research, and are able to undergo the pre-test specified in the research protocol, and report subjective symptoms, etc.
- •4) Those who have been judged eligible for participation in this study by the pysician in charge of the research or othewe relevant personnel based on a preliminary examination as stipulated in the research protocol.
排除标准
- •1) Persons with a medical history (drug abuse/dependence, alcohol abuse/dependence, heart, liver, kidney, lung, eye, or blood disease, etc.) that may affect the evaluation and safety of this study.
- •2) Themselves, whose parents, or siblings are prone to allergic symptoms such as bronchial asthma, rash, urticaria, etc.
- •3) Persons with epilepsy or other convulsive disorders or a history of such disorders
- •4) Persons with a history of aortic aneurysm or aortic dissection, family history, or risk factors (congenital connective tissue abnormalities such as Marfan syndrome).
- •5) Persons taking medications (including supplements and dietary supplements) that may affect the evaluation and safety of this study.
- •6) Persons with a history of drug allergy.
- •7) Persons who regularly use excessive amounts of alcohol (those who cannot maintain abstinence from alcohol during the study period)
- •8) Those who are within three months of participating in another clinical research study
- •9) Any other person who judges by the investigator to be ineligible for the study.
研究者
相似试验
已完成
4 期
Examining whether any interactions occur between the antibiotic Ciprofloxacin and the antimalarial treatment Chloroquine/ProguanilPharmacokineticsISRCTN20647977Defence Science and Technology Laboratory (Dstl)16
进行中(未招募)
1 期
Pharmacokinetic Interactions between Ciprofloxacin and Chloroquine / Proguanil ProphylaxisChloroquine/proguanil is used for malaria chemoprophylaxis in areas where chloroquine-resistant Plasmodium falciparum malaria is prevalent, except in regions of Africa where chloroquine/proguanil is no longer effective. Ciprofloxacin is a fluoroquinolone antibiotic used to treat a wide variety of infections, such as traveller`s diarrhoea. Only healthy subjects will be treated in this study.EUCTR2005-004905-27-GBDstl16
已完成
1 期
Impact of Formulation on Ciprofloxacin Oral AbsorptionHealthyNCT00992329University of Maryland, Baltimore16
已完成
4 期
Ciprofloxacin pharmacokinetics after IV and oral administration in cachectic elderly patients10004018PneumoniacystitisUrinary tract infectionNL-OMON50150Tergooiziekenhuizen25
已完成
不适用
To study ciprofloxacin pharmacokinetics in patients who are critically ill and undergoing continuous dialysisPatients on dialysisNutritional, Metabolic, EndocrineRenal failureISRCTN52722850Trinity College Dublin (Ireland)7
